Stomach Cancer Research
Nivolumab Improves Survival for Some Patients with Advanced Stomach CancerPosted:
For some people with advanced stomach cancer, the drug nivolumab (Opdivo) plus chemotherapy may improve how long they live, results from a large clinical trial show. The trial also included patients with gastric cancers that involve the esophagus.
Incidence of Cancers of the Lower Stomach Increasing among Younger AmericansPosted:
A type of cancer that occurs in the lower stomach has been increasing among some Americans under the age of 50, even though in the general population the incidence of all stomach cancers has been declining for decades, according to a new study.
Pembrolizumab Secures FDA Approval in Stomach CancerPosted:
The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.
TCGA researchers identify four subtypes of stomach cancerPosted:
Stomach cancers fall into four distinct molecular subtypes, researchers with The Cancer Genome Atlas (TCGA) Network have found. Scientists report that this discovery could change how researchers think about developing treatments for stomach cancer, also called gastric cancers or gastric adenocarcinomas.
Chemotherapy Before Surgery May Increase Survival in Stomach CancerUpdated:
Chemotherapy given before surgery for cancer of the lower esophagus and stomach increased the number of patients surviving for five years compared to surgery alone, according to findings presented at the 2007 ASCO meeting in Chicago.